These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27896588)

  • 1. Electrosprayed Myocet-like Liposomes: An Alternative to Traditional Liposome Production.
    Collier MA; Bachelder EM; Ainslie KM
    Pharm Res; 2017 Feb; 34(2):419-426. PubMed ID: 27896588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations.
    Luo R; Li Y; He M; Zhang H; Yuan H; Johnson M; Palmisano M; Zhou S; Sun D
    Int J Pharm; 2017 Mar; 519(1-2):1-10. PubMed ID: 28063903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
    Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
    Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
    Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
    J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil).
    Tsukioka Y; Matsumura Y; Hamaguchi T; Koike H; Moriyasu F; Kakizoe T
    Jpn J Cancer Res; 2002 Oct; 93(10):1145-53. PubMed ID: 12417045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
    Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
    Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release.
    Nagpal S; Braner S; Modh H; Tan AXX; Mast MP; Chichakly K; Albrecht V; Wacker MG
    Eur J Pharm Biopharm; 2020 Aug; 153():257-272. PubMed ID: 32589926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin.
    Evjen TJ; Hagtvet E; Nilssen EA; Brandl M; Fossheim SL
    Eur J Pharm Sci; 2011 Jul; 43(4):318-24. PubMed ID: 21620968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
    Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
    Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal Doxorubicin Delivery Systems: Effects of Formulation and Processing Parameters on Drug Loading and Release Behavior.
    Mohammadi ZA; Aghamiri SF; Zarrabi A; Talaie MR
    Curr Drug Deliv; 2016; 13(7):1065-1070. PubMed ID: 26708673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From conventional to stealth liposomes: a new frontier in cancer chemotherapy.
    Cattel L; Ceruti M; Dosio F
    Tumori; 2003; 89(3):237-49. PubMed ID: 12908776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aptamer-based liposomes improve specific drug loading and release.
    Plourde K; Derbali RM; Desrosiers A; Dubath C; Vallée-Bélisle A; Leblond J
    J Control Release; 2017 Apr; 251():82-91. PubMed ID: 28238787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug candidates for liposomal delivery identified by computer modeling of liposomes' remote loading and leakage.
    Cern A; Marcus D; Tropsha A; Barenholz Y; Goldblum A
    J Control Release; 2017 Apr; 252():18-27. PubMed ID: 28215669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an in vitro drug release assay of PEGylated liposome using bovine serum albumin and high temperature.
    Hioki A; Wakasugi A; Kawano K; Hattori Y; Maitani Y
    Biol Pharm Bull; 2010; 33(9):1466-70. PubMed ID: 20823558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
    Ishida T; Atobe K; Wang X; Kiwada H
    J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes.
    Yuan W; Kuai R; Dai Z; Yuan Y; Zheng N; Jiang W; Noble C; Hayes M; Szoka FC; Schwendeman A
    AAPS J; 2017 Jan; 19(1):150-160. PubMed ID: 27485642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heating treatments affect the thermal behaviour of doxorubicin loaded in PEGylated liposomes.
    Perinelli DR; Cespi M; Bonacucina G; Rendina F; Palmieri GF
    Int J Pharm; 2017 Dec; 534(1-2):81-88. PubMed ID: 28993166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic model and analysis of doxorubicin release from liposomal formulations.
    Fugit KD; Xiang TX; Choi du H; Kangarlou S; Csuhai E; Bummer PM; Anderson BD
    J Control Release; 2015 Nov; 217():82-91. PubMed ID: 26310713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.